Ailin Shi has a robust background in clinical quality management and auditing, with significant experience in the pharmaceutical industry. Ailin served as Associate Director of Clinical Quality Management at Merck Group from 2017 to 2018 and also worked as a Clinical QA Auditor at PPD from 2010 to 2012. From 2018 to 2021, Ailin held the position of Associate Director of Clinical & Pharmacovigilance QA for Asia Pacific at AstraZeneca. Currently, Ailin is the Head of GCP Study Audit Management for China at Bayer Pharmaceuticals Asia-Pacific, a role commenced in August 2021, after previously serving as R&D QA for Asia Pacific at the same company from 2012 to 2017.
This person is not in the org chart
This person is not in any teams
This person is not in any offices